Abstract
Advances in genetic and epigenetic analyses and immunohistochemical studies involving the development of mutation-specific or histone-methylated antibodies have provided many significant findings about gliomas. Based on these findings, the WHO developed and published the classification of tumors of the central nervous system in 2016. In the classification system, molecular information was combined with pathological findings. After its publication, the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official WHO(cIMAPCT-NOW)was published to evaluate and recommend changes to future central nervous system tumor classifications. This review describes the genetic and epigenetic features of gliomas, mainly those associated with the WHO classification and cIMPACT-NOW.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
